Redeye sees Immunicum as a more dynamic entity following the acquisition of DCprime, and the transaction strengthens the team and ownership base significantly. However, the value of DCprime’s asset DCP-001 will be highly dependent on the outcome in an ongoing Phase II trial. In the short term, significant dilution prompts us to lower the base case to SEK 12 (16.5).